Biolase Stock Beta
| BIOLDelisted Stock | USD 0.05 0.02 27.46% |
BIOLASE fundamentals help investors to digest information that contributes to BIOLASE's financial success or failures. It also enables traders to predict the movement of BIOLASE Stock. The fundamental analysis module provides a way to measure BIOLASE's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to BIOLASE stock.
BIOLASE |
BIOLASE Company Beta Analysis
BIOLASE's Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Current BIOLASE Beta | 0.75 |
Most of BIOLASE's fundamental indicators, such as Beta, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, BIOLASE is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
CompetitionIn accordance with the recently published financial statements, BIOLASE has a Beta of 0.749. This is 12.91% lower than that of the Health Care Equipment & Supplies sector and 27.98% lower than that of the Health Care industry. The beta for all United States stocks is notably lower than that of the firm.
BIOLASE Beta Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses BIOLASE's direct or indirect competition against its Beta to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of BIOLASE could also be used in its relative valuation, which is a method of valuing BIOLASE by comparing valuation metrics of similar companies.BIOLASE is currently under evaluation in beta category among its peers.
As returns on the market increase, BIOLASE's returns are expected to increase less than the market. However, during the bear market, the loss of holding BIOLASE is expected to be smaller as well.
BIOLASE Fundamentals
| Return On Equity | -5.05 | |||
| Return On Asset | -0.27 | |||
| Profit Margin | (0.44) % | |||
| Operating Margin | (0.45) % | |||
| Current Valuation | 13.65 M | |||
| Shares Outstanding | 33.4 M | |||
| Shares Owned By Insiders | 0.32 % | |||
| Shares Owned By Institutions | 8.97 % | |||
| Number Of Shares Shorted | 2.1 M | |||
| Price To Earning | (7.23) X | |||
| Price To Book | 0.77 X | |||
| Price To Sales | 0.1 X | |||
| Revenue | 49.16 M | |||
| Gross Profit | 16.53 M | |||
| EBITDA | (15.14 M) | |||
| Net Income | (20.63 M) | |||
| Cash And Equivalents | 9.96 M | |||
| Cash Per Share | 1.39 X | |||
| Total Debt | 17.91 M | |||
| Debt To Equity | 1.07 % | |||
| Current Ratio | 2.46 X | |||
| Book Value Per Share | (0.06) X | |||
| Cash Flow From Operations | (14.09 M) | |||
| Short Ratio | 1.09 X | |||
| Earnings Per Share | (11.97) X | |||
| Price To Earnings To Growth | (0.22) X | |||
| Target Price | 1.95 | |||
| Number Of Employees | 157 | |||
| Beta | 0.75 | |||
| Market Capitalization | 4.31 M | |||
| Total Asset | 35.1 M | |||
| Retained Earnings | (316.8 M) | |||
| Working Capital | 5.2 M | |||
| Current Asset | 34.8 M | |||
| Current Liabilities | 15.11 M | |||
| Net Asset | 35.1 M |
About BIOLASE Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze BIOLASE's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BIOLASE using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BIOLASE based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Other Consideration for investing in BIOLASE Stock
If you are still planning to invest in BIOLASE check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the BIOLASE's history and understand the potential risks before investing.
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume |